Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Clovis’ development programs are targeted at specific subsets of cancer, combining precision medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from their use. Clovis believes this approach to precision medicine – to deliver the right dr
BOULDER, Colo.--(BUSINESS WIRE)--Feb. 12, 2018--
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its fourth quarter
and full year 2017 financial results on Monday, February 26, 2018, after
the close of the U.S. financial markets. Clovis’ senior management will
host a conference call and live audio webcast at 4:30 p.m. ET to discuss
the company’s results in greater detail.
The conference call is being webcast and can be accessed from the Clovis...
BOULDER, Colo.--(BUSINESS WIRE)--Jan. 4, 2018--
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its Chief
Executive Officer and President, Patrick J. Mahaffy, will present at the
36th Annual J.P. Morgan Healthcare Conference on Tuesday, January 9,
2018 at 2:30 PM Pacific Time. The conference will be held at the Westin
St. Francis Hotel in San Francisco.
A live webcast of the presentation and breakout session can be accessed
Treatment indication remains under active review
The Scientific Advisory Group advice will assist CHMP to reach a
positive or negative opinion
In January 2018, the Company plans to notify the EMA of its intent
to submit a new MAA in Q2 2018 for the maintenance treatment
indication in women with advanced ovarian cancer
In the event of a positive CHMP opinion and corresponding EMA
Sign up to receive email alerts whenever Clovis Oncology, Inc. posts new information to the site. Just enter your email address and click Submit.
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.